{ "pack_version": "ud-trial-provenance/0.1", "pack_id": "tpp-23c7359f72fc95c70cf74fcb", "generated_at": "2026-09-21T15:03:31.075Z", "trial": { "canonical_trial_id": "NCT04280705", "registry": "ClinicalTrials.gov", "registry_url": "https://clinicaltrials.gov/study/NCT04280705", "first_seen_at": "2026-09-21T15:03:27.536Z", "last_checked_at": "2026-09-21T15:03:27.536Z" }, "fields": { "brief_title": "Adaptive COVID-19 Treatment Trial (ACTT)", "official_title": "A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults", "overall_status": "COMPLETED", "phase": [ "PHASE3" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "collaborators": [], "enrollment": 1062, "enrollment_type": "ACTUAL", "interventions": [ { "type": "OTHER", "name": "Placebo" }, { "type": "DRUG", "name": "Remdesivir" } ], "conditions": [ "COVID-19" ], "primary_outcomes": [ { "measure": "Time to Recovery", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Race", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Ethnicity", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Sex", "timeFrame": "Day 1 through Day 29" } ], "secondary_outcomes": [ { "measure": "Change From Baseline in Alanine Transaminase (ALT)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Aspartate Transaminase (AST)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Creatinine", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Glucose", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Hemoglobin", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Platelets", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Prothrombin Time (PT)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Total Bilirubin", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in White Blood Cell Count (WBC)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Neutrophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Lymphocytes", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Monocytes", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Basophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Eosinophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change in National Early Warning Score (NEWS) From Baseline", "timeFrame": "Days 1, 3, 5, 8, 11, 15, 22, and 29" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1", "timeFrame": "Day 1" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3", "timeFrame": "Day 3" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5", "timeFrame": "Day 5" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8", "timeFrame": "Day 8" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11", "timeFrame": "Day 11" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15", "timeFrame": "Day 15" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22", "timeFrame": "Day 22" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29", "timeFrame": "Day 29" }, { "measure": "Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Reporting Serious Adverse Events (SAEs)", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics", "timeFrame": "Day 1 through Day 10" }, { "measure": "Duration of Hospitalization", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Non-invasive Ventilation or High Flow Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Mean Change in the Ordinal Scale", "timeFrame": "Day 1, 3, 5, 8, 11, 15, 22, and 29" }, { "measure": "14-day Participant Mortality", "timeFrame": "Day 1 through Day 15" }, { "measure": "29-day Participant Mortality", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to an Improvement by at Least One Category Using an Ordinal Scale", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to an Improvement of at Least Two Categories Using an Ordinal Scale", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First", "timeFrame": "Day 1 through Day 29" } ], "start_date": "2020-02-21", "primary_completion_date": "2020-05-21", "study_completion_date": "2020-05-21", "study_type": "INTERVENTIONAL" }, "sources": [ { "source_id": "src-0714e354de52ea589705", "source_type": "CLINICALTRIALS_GOV_RECORD", "tier": 1, "canonical_url": "https://clinicaltrials.gov/study/NCT04280705", "external_identifier": "NCT04280705", "publisher": "U.S. National Library of Medicine", "published_at": null, "retrieved_at": "2026-09-21T15:03:27.536Z", "content_hash": "5b010cf5754d3deb521279f616257b7cba726dd290ec972f65ffd6bde8f3eb68", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, { "source_id": "src-e33b53de92a28214a7ed", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/38657001/", "external_identifier": "38657001", "publisher": "The Journal of infectious diseases", "published_at": "2024 Sep 23", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "0e4c46e6096860920954c473770ab217390bb2e5b0af1912a89fa666047aac8e", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, { "source_id": "src-280ba46f5c13688192fc", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/38618926/", "external_identifier": "38618926", "publisher": "Clinical trials (London, England)", "published_at": "2024 Aug", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "ee7e5aa9bb7e37fe7d7ed0d9b7b1bca4388d606ab855cf90a916453acb4fd3f2", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, { "source_id": "src-a372d48de6ecf155eb2a", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/37466213/", "external_identifier": "37466213", "publisher": "The Journal of infectious diseases", "published_at": "2023 Nov 2", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "bc4e4c5d1d8333010c92d472d492c82d4ac6e52c7bb0af5ca3ee2d42b00ea0ed", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, { "source_id": "src-6f87ad713e55332e03b9", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/36695483/", "external_identifier": "36695483", "publisher": "The Cochrane database of systematic reviews", "published_at": "2023 Jan 25", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "c8b1f8c501ee03038c43e67baa261848216b51415b8689b0477d6c652b15c8c6", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, { "source_id": "src-1088878b86de4a9de905", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/36442063/", "external_identifier": "36442063", "publisher": "Annals of internal medicine", "published_at": "2022 Dec", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "1df93cf2e44f596e0bb9fb24f09141ae88de02059b141a0cae091e9f8fe555b9", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, { "source_id": "src-4daa19a90a25dd5e6723", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/34473343/", "external_identifier": "34473343", "publisher": "The Cochrane database of systematic reviews", "published_at": "2021 Sep 2", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "5c89b68bdfd8c14fd1269375128cf43e70345ae275e48efdefc198b2b6e43ac6", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, { "source_id": "src-305c36d00080bbb08a75", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/34350582/", "external_identifier": "34350582", "publisher": "The Cochrane database of systematic reviews", "published_at": "2021 Aug 5", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "8d6a4c53124a52cdb153b2522e1958c4d4e280384bc73ddbf972f1f418ea8b33", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, { "source_id": "src-e20c7e961d6eb8b0972c", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/33240091/", "external_identifier": "33240091", "publisher": "Frontiers in pharmacology", "published_at": "2020", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "16e5379d39a6d44b6c55415c7e55f532ff24a5e4e86693134793b7bef2756ca6", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, { "source_id": "src-a87c29d74e6d92ae5bd1", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/32969710/", "external_identifier": "32969710", "publisher": "Circulation", "published_at": "2021 Mar 30", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "1dd84b64a9a198211c99a52910c65b84843abbf9e3001233adb9dced091c21ab", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, { "source_id": "src-8edfd124b2fb597b54de", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/32445440/", "external_identifier": "32445440", "publisher": "The New England journal of medicine", "published_at": "2020 Nov 5", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "e1948448f118d49ff869d3ee950273b4d685748a6cb75cbfb94bb285923b9193", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" } ], "observations": [ { "trial_id": "NCT04280705", "field_name": "brief_title", "normalized_value": "Adaptive COVID-19 Treatment Trial (ACTT)", "raw_value": "Adaptive COVID-19 Treatment Trial (ACTT)", "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "c913226768817e884d60fe0f65fe658087f8d51a2f2fbed9a688cf3b3d48c517" }, { "trial_id": "NCT04280705", "field_name": "official_title", "normalized_value": "A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults", "raw_value": "A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults", "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "b00b91b96d8c4fad845c1eba38182290a70e189a8703a67f97a5243b33fb7415" }, { "trial_id": "NCT04280705", "field_name": "overall_status", "normalized_value": "COMPLETED", "raw_value": "COMPLETED", "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "b8171c2cb388819b4627328bcfa356c735d8f0f2681a4cec40bdaf6bc726d5f0" }, { "trial_id": "NCT04280705", "field_name": "phase", "normalized_value": [ "PHASE3" ], "raw_value": [ "PHASE3" ], "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "b133b8b62c441959a32062fae42b27bbeddd829b45e1138234fb997a287dd60b" }, { "trial_id": "NCT04280705", "field_name": "sponsor", "normalized_value": "National Institute of Allergy and Infectious Diseases (NIAID)", "raw_value": "National Institute of Allergy and Infectious Diseases (NIAID)", "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "37ad5b24c5d3b09bba7d7381dc9344cba41a0a5951498d33e49cea52647260ca" }, { "trial_id": "NCT04280705", "field_name": "collaborators", "normalized_value": [], "raw_value": [], "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "325170ec30d5720c3496d25569e2c68c314d194d784c5a07d6eda5aac9217e62" }, { "trial_id": "NCT04280705", "field_name": "enrollment", "normalized_value": 1062, "raw_value": 1062, "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "7ec5af16fed74b11a0fa317e79802cada5ad47d6cbffe2e990b91e7c9eb5add0" }, { "trial_id": "NCT04280705", "field_name": "enrollment_type", "normalized_value": "ACTUAL", "raw_value": "ACTUAL", "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "65d68e65a976126535d6e97943a5c4db8e86f7b4f874c69ec28f481d75d015d7" }, { "trial_id": "NCT04280705", "field_name": "interventions", "normalized_value": [ { "type": "OTHER", "name": "Placebo" }, { "type": "DRUG", "name": "Remdesivir" } ], "raw_value": [ { "type": "OTHER", "name": "Placebo" }, { "type": "DRUG", "name": "Remdesivir" } ], "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "381c8d0109d61060d5d0d73302cc77837e42257a5affcca2984aa16e1e68f072" }, { "trial_id": "NCT04280705", "field_name": "conditions", "normalized_value": [ "COVID-19" ], "raw_value": [ "COVID-19" ], "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "9af532adc3156ef2b320bda648caaa0c5685bad443c72e4ee83603275c65f40f" }, { "trial_id": "NCT04280705", "field_name": "primary_outcomes", "normalized_value": [ { "measure": "Time to Recovery", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Race", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Ethnicity", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Sex", "timeFrame": "Day 1 through Day 29" } ], "raw_value": [ { "measure": "Time to Recovery", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Race", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Ethnicity", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Sex", "timeFrame": "Day 1 through Day 29" } ], "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "16cd0db101d54d53d7f6e9daf4521e86f40c4a32898767b9a0bd1a9cc59ffc81" }, { "trial_id": "NCT04280705", "field_name": "secondary_outcomes", "normalized_value": [ { "measure": "Change From Baseline in Alanine Transaminase (ALT)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Aspartate Transaminase (AST)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Creatinine", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Glucose", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Hemoglobin", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Platelets", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Prothrombin Time (PT)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Total Bilirubin", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in White Blood Cell Count (WBC)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Neutrophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Lymphocytes", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Monocytes", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Basophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Eosinophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change in National Early Warning Score (NEWS) From Baseline", "timeFrame": "Days 1, 3, 5, 8, 11, 15, 22, and 29" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1", "timeFrame": "Day 1" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3", "timeFrame": "Day 3" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5", "timeFrame": "Day 5" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8", "timeFrame": "Day 8" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11", "timeFrame": "Day 11" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15", "timeFrame": "Day 15" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22", "timeFrame": "Day 22" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29", "timeFrame": "Day 29" }, { "measure": "Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Reporting Serious Adverse Events (SAEs)", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics", "timeFrame": "Day 1 through Day 10" }, { "measure": "Duration of Hospitalization", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Non-invasive Ventilation or High Flow Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Mean Change in the Ordinal Scale", "timeFrame": "Day 1, 3, 5, 8, 11, 15, 22, and 29" }, { "measure": "14-day Participant Mortality", "timeFrame": "Day 1 through Day 15" }, { "measure": "29-day Participant Mortality", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to an Improvement by at Least One Category Using an Ordinal Scale", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to an Improvement of at Least Two Categories Using an Ordinal Scale", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First", "timeFrame": "Day 1 through Day 29" } ], "raw_value": [ { "measure": "Change From Baseline in Alanine Transaminase (ALT)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Aspartate Transaminase (AST)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Creatinine", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Glucose", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Hemoglobin", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Platelets", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Prothrombin Time (PT)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Total Bilirubin", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in White Blood Cell Count (WBC)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Neutrophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Lymphocytes", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Monocytes", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Basophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Eosinophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change in National Early Warning Score (NEWS) From Baseline", "timeFrame": "Days 1, 3, 5, 8, 11, 15, 22, and 29" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1", "timeFrame": "Day 1" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3", "timeFrame": "Day 3" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5", "timeFrame": "Day 5" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8", "timeFrame": "Day 8" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11", "timeFrame": "Day 11" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15", "timeFrame": "Day 15" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22", "timeFrame": "Day 22" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29", "timeFrame": "Day 29" }, { "measure": "Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Reporting Serious Adverse Events (SAEs)", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics", "timeFrame": "Day 1 through Day 10" }, { "measure": "Duration of Hospitalization", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Non-invasive Ventilation or High Flow Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Mean Change in the Ordinal Scale", "timeFrame": "Day 1, 3, 5, 8, 11, 15, 22, and 29" }, { "measure": "14-day Participant Mortality", "timeFrame": "Day 1 through Day 15" }, { "measure": "29-day Participant Mortality", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to an Improvement by at Least One Category Using an Ordinal Scale", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to an Improvement of at Least Two Categories Using an Ordinal Scale", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First", "timeFrame": "Day 1 through Day 29" } ], "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "501ed0140ea7e752087a8e4b26f0146dfe51a1a32257f8182c8e5e38e0beea10" }, { "trial_id": "NCT04280705", "field_name": "start_date", "normalized_value": "2020-02-21", "raw_value": "2020-02-21", "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "3dc01f4cf36a0500fc7ccdcf953334f7331f5f44d83bc4255f822ff029698bc8" }, { "trial_id": "NCT04280705", "field_name": "primary_completion_date", "normalized_value": "2020-05-21", "raw_value": "2020-05-21", "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "efe72d8b1f529e9c011d3430e1787ae298c612beff65a8b5560ad01596697e86" }, { "trial_id": "NCT04280705", "field_name": "study_completion_date", "normalized_value": "2020-05-21", "raw_value": "2020-05-21", "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "dced5d73140c5f3f3c5434d6ac1df35c6791b2efb1405fd7ceb239ef38e5f63c" }, { "trial_id": "NCT04280705", "field_name": "study_type", "normalized_value": "INTERVENTIONAL", "raw_value": "INTERVENTIONAL", "source_id": "src-0714e354de52ea589705", "retrieved_at": "2026-09-21T15:03:27.536Z", "observation_hash": "f7b1e19d03059dc5e10621106444841e1e5af9adbfe29df6085d20efca1d4d89" } ], "claims": [ { "claim_id": "claim-514793bbf6d26c5c0fd8", "subject": "NCT04280705", "predicate": "brief_title", "value": "Adaptive COVID-19 Treatment Trial (ACTT)", "normalized_value": "Adaptive COVID-19 Treatment Trial (ACTT)", "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-3b6deb04e6f2b79d30f8", "subject": "NCT04280705", "predicate": "official_title", "value": "A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults", "normalized_value": "A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults", "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-af6f32353b9842844b0c", "subject": "NCT04280705", "predicate": "overall_status", "value": "COMPLETED", "normalized_value": "COMPLETED", "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-11f4096d6f4dba0fd5a3", "subject": "NCT04280705", "predicate": "phase", "value": [ "PHASE3" ], "normalized_value": [ "PHASE3" ], "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-482a11900da6442717c3", "subject": "NCT04280705", "predicate": "sponsor", "value": "National Institute of Allergy and Infectious Diseases (NIAID)", "normalized_value": "National Institute of Allergy and Infectious Diseases (NIAID)", "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-6d02788df0e7c42da57e", "subject": "NCT04280705", "predicate": "collaborators", "value": [], "normalized_value": [], "claim_type": "UNKNOWN", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-87efa6188a55930a59ea", "subject": "NCT04280705", "predicate": "enrollment", "value": 1062, "normalized_value": 1062, "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-d25b1c62e7054a7c8ec3", "subject": "NCT04280705", "predicate": "enrollment_type", "value": "ACTUAL", "normalized_value": "ACTUAL", "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-eea61467115ff861ccfc", "subject": "NCT04280705", "predicate": "interventions", "value": [ { "type": "OTHER", "name": "Placebo" }, { "type": "DRUG", "name": "Remdesivir" } ], "normalized_value": [ { "type": "OTHER", "name": "Placebo" }, { "type": "DRUG", "name": "Remdesivir" } ], "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-f124e940921d3a520ea7", "subject": "NCT04280705", "predicate": "conditions", "value": [ "COVID-19" ], "normalized_value": [ "COVID-19" ], "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-d608de3365e5f7650f76", "subject": "NCT04280705", "predicate": "primary_outcomes", "value": [ { "measure": "Time to Recovery", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Race", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Ethnicity", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Sex", "timeFrame": "Day 1 through Day 29" } ], "normalized_value": [ { "measure": "Time to Recovery", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Race", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Ethnicity", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Recovery by Sex", "timeFrame": "Day 1 through Day 29" } ], "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-d6168c5cf2f8e768cd3c", "subject": "NCT04280705", "predicate": "secondary_outcomes", "value": [ { "measure": "Change From Baseline in Alanine Transaminase (ALT)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Aspartate Transaminase (AST)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Creatinine", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Glucose", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Hemoglobin", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Platelets", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Prothrombin Time (PT)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Total Bilirubin", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in White Blood Cell Count (WBC)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Neutrophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Lymphocytes", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Monocytes", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Basophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Eosinophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change in National Early Warning Score (NEWS) From Baseline", "timeFrame": "Days 1, 3, 5, 8, 11, 15, 22, and 29" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1", "timeFrame": "Day 1" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3", "timeFrame": "Day 3" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5", "timeFrame": "Day 5" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8", "timeFrame": "Day 8" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11", "timeFrame": "Day 11" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15", "timeFrame": "Day 15" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22", "timeFrame": "Day 22" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29", "timeFrame": "Day 29" }, { "measure": "Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Reporting Serious Adverse Events (SAEs)", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics", "timeFrame": "Day 1 through Day 10" }, { "measure": "Duration of Hospitalization", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Non-invasive Ventilation or High Flow Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Mean Change in the Ordinal Scale", "timeFrame": "Day 1, 3, 5, 8, 11, 15, 22, and 29" }, { "measure": "14-day Participant Mortality", "timeFrame": "Day 1 through Day 15" }, { "measure": "29-day Participant Mortality", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to an Improvement by at Least One Category Using an Ordinal Scale", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to an Improvement of at Least Two Categories Using an Ordinal Scale", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First", "timeFrame": "Day 1 through Day 29" } ], "normalized_value": [ { "measure": "Change From Baseline in Alanine Transaminase (ALT)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Aspartate Transaminase (AST)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Creatinine", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Glucose", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Hemoglobin", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Platelets", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Prothrombin Time (PT)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Total Bilirubin", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in White Blood Cell Count (WBC)", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Neutrophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Lymphocytes", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Monocytes", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Basophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change From Baseline in Eosinophils", "timeFrame": "Days 1, 3, 5, 8, 11, 15 and 29" }, { "measure": "Change in National Early Warning Score (NEWS) From Baseline", "timeFrame": "Days 1, 3, 5, 8, 11, 15, 22, and 29" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1", "timeFrame": "Day 1" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3", "timeFrame": "Day 3" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5", "timeFrame": "Day 5" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8", "timeFrame": "Day 8" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11", "timeFrame": "Day 11" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15", "timeFrame": "Day 15" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22", "timeFrame": "Day 22" }, { "measure": "Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29", "timeFrame": "Day 29" }, { "measure": "Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Reporting Serious Adverse Events (SAEs)", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics", "timeFrame": "Day 1 through Day 10" }, { "measure": "Duration of Hospitalization", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Non-invasive Ventilation or High Flow Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Oxygen Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use", "timeFrame": "Day 1 through Day 29" }, { "measure": "Mean Change in the Ordinal Scale", "timeFrame": "Day 1, 3, 5, 8, 11, 15, 22, and 29" }, { "measure": "14-day Participant Mortality", "timeFrame": "Day 1 through Day 15" }, { "measure": "29-day Participant Mortality", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to an Improvement by at Least One Category Using an Ordinal Scale", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to an Improvement of at Least Two Categories Using an Ordinal Scale", "timeFrame": "Day 1 through Day 29" }, { "measure": "Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First", "timeFrame": "Day 1 through Day 29" } ], "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-ee947903d4a7a5af8cf2", "subject": "NCT04280705", "predicate": "start_date", "value": "2020-02-21", "normalized_value": "2020-02-21", "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-e1e8705c1371bad57cdd", "subject": "NCT04280705", "predicate": "primary_completion_date", "value": "2020-05-21", "normalized_value": "2020-05-21", "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-1d6e2656a029e59e4be6", "subject": "NCT04280705", "predicate": "study_completion_date", "value": "2020-05-21", "normalized_value": "2020-05-21", "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" }, { "claim_id": "claim-70bad6858201db8c1e55", "subject": "NCT04280705", "predicate": "study_type", "value": "INTERVENTIONAL", "normalized_value": "INTERVENTIONAL", "claim_type": "SOURCE_FACT", "observed_at": "2026-09-21T15:03:27.536Z", "created_at": "2026-09-21T15:03:27.536Z" } ], "claim_support": [ { "claim_id": "claim-514793bbf6d26c5c0fd8", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.identificationModule.briefTitle", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-3b6deb04e6f2b79d30f8", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.identificationModule.officialTitle", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-af6f32353b9842844b0c", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.statusModule.overallStatus", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-11f4096d6f4dba0fd5a3", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.designModule.phases", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-482a11900da6442717c3", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.sponsorCollaboratorsModule.leadSponsor.name", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-87efa6188a55930a59ea", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.designModule.enrollmentInfo.count", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-d25b1c62e7054a7c8ec3", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.designModule.enrollmentInfo.type", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-eea61467115ff861ccfc", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.armsInterventionsModule.interventions", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-f124e940921d3a520ea7", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.conditionsModule.conditions", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-d608de3365e5f7650f76", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.outcomesModule.primaryOutcomes", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-d6168c5cf2f8e768cd3c", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.outcomesModule.secondaryOutcomes", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-ee947903d4a7a5af8cf2", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.statusModule.startDateStruct.date", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-e1e8705c1371bad57cdd", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.statusModule.primaryCompletionDateStruct.date", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-1d6e2656a029e59e4be6", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.statusModule.completionDateStruct.date", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" }, { "claim_id": "claim-70bad6858201db8c1e55", "source_id": "src-0714e354de52ea589705", "exact_locator": "protocolSection.designModule.studyType", "relationship": "SUPPORTS", "confidence": 1, "reviewer_state": "DIRECT_STRUCTURED_FIELD" } ], "publications": [ { "pmid": "38657001", "title": "SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.", "source": { "source_id": "src-e33b53de92a28214a7ed", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/38657001/", "external_identifier": "38657001", "publisher": "The Journal of infectious diseases", "published_at": "2024 Sep 23", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "0e4c46e6096860920954c473770ab217390bb2e5b0af1912a89fa666047aac8e", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, "relationship": "DIRECT_TRIAL_PUBLICATION", "relationship_basis": "PubMed indexed record returned for exact NCT04280705 identifier query", "confidence": 1 }, { "pmid": "38618926", "title": "Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials.", "source": { "source_id": "src-280ba46f5c13688192fc", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/38618926/", "external_identifier": "38618926", "publisher": "Clinical trials (London, England)", "published_at": "2024 Aug", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "ee7e5aa9bb7e37fe7d7ed0d9b7b1bca4388d606ab855cf90a916453acb4fd3f2", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, "relationship": "DIRECT_TRIAL_PUBLICATION", "relationship_basis": "PubMed indexed record returned for exact NCT04280705 identifier query", "confidence": 1 }, { "pmid": "37466213", "title": "Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1).", "source": { "source_id": "src-a372d48de6ecf155eb2a", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/37466213/", "external_identifier": "37466213", "publisher": "The Journal of infectious diseases", "published_at": "2023 Nov 2", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "bc4e4c5d1d8333010c92d472d492c82d4ac6e52c7bb0af5ca3ee2d42b00ea0ed", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, "relationship": "DIRECT_TRIAL_PUBLICATION", "relationship_basis": "PubMed indexed record returned for exact NCT04280705 identifier query", "confidence": 1 }, { "pmid": "36695483", "title": "Remdesivir for the treatment of COVID-19.", "source": { "source_id": "src-6f87ad713e55332e03b9", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/36695483/", "external_identifier": "36695483", "publisher": "The Cochrane database of systematic reviews", "published_at": "2023 Jan 25", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "c8b1f8c501ee03038c43e67baa261848216b51415b8689b0477d6c652b15c8c6", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, "relationship": "DIRECT_TRIAL_PUBLICATION", "relationship_basis": "PubMed indexed record returned for exact NCT04280705 identifier query", "confidence": 1 }, { "pmid": "36442063", "title": "Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial.", "source": { "source_id": "src-1088878b86de4a9de905", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/36442063/", "external_identifier": "36442063", "publisher": "Annals of internal medicine", "published_at": "2022 Dec", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "1df93cf2e44f596e0bb9fb24f09141ae88de02059b141a0cae091e9f8fe555b9", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, "relationship": "DIRECT_TRIAL_PUBLICATION", "relationship_basis": "PubMed indexed record returned for exact NCT04280705 identifier query", "confidence": 1 }, { "pmid": "34473343", "title": "SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.", "source": { "source_id": "src-4daa19a90a25dd5e6723", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/34473343/", "external_identifier": "34473343", "publisher": "The Cochrane database of systematic reviews", "published_at": "2021 Sep 2", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "5c89b68bdfd8c14fd1269375128cf43e70345ae275e48efdefc198b2b6e43ac6", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, "relationship": "DIRECT_TRIAL_PUBLICATION", "relationship_basis": "PubMed indexed record returned for exact NCT04280705 identifier query", "confidence": 1 }, { "pmid": "34350582", "title": "Remdesivir for the treatment of COVID-19.", "source": { "source_id": "src-305c36d00080bbb08a75", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/34350582/", "external_identifier": "34350582", "publisher": "The Cochrane database of systematic reviews", "published_at": "2021 Aug 5", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "8d6a4c53124a52cdb153b2522e1958c4d4e280384bc73ddbf972f1f418ea8b33", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, "relationship": "DIRECT_TRIAL_PUBLICATION", "relationship_basis": "PubMed indexed record returned for exact NCT04280705 identifier query", "confidence": 1 }, { "pmid": "33240091", "title": "Challenges for Drug Repurposing in the COVID-19 Pandemic Era.", "source": { "source_id": "src-e20c7e961d6eb8b0972c", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/33240091/", "external_identifier": "33240091", "publisher": "Frontiers in pharmacology", "published_at": "2020", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "16e5379d39a6d44b6c55415c7e55f532ff24a5e4e86693134793b7bef2756ca6", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, "relationship": "DIRECT_TRIAL_PUBLICATION", "relationship_basis": "PubMed indexed record returned for exact NCT04280705 identifier query", "confidence": 1 }, { "pmid": "32969710", "title": "Urgent Need for Studies of the Late Effects of SARS-CoV-2 on the Cardiovascular System.", "source": { "source_id": "src-a87c29d74e6d92ae5bd1", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/32969710/", "external_identifier": "32969710", "publisher": "Circulation", "published_at": "2021 Mar 30", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "1dd84b64a9a198211c99a52910c65b84843abbf9e3001233adb9dced091c21ab", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, "relationship": "DIRECT_TRIAL_PUBLICATION", "relationship_basis": "PubMed indexed record returned for exact NCT04280705 identifier query", "confidence": 1 }, { "pmid": "32445440", "title": "Remdesivir for the Treatment of Covid-19 - Final Report.", "source": { "source_id": "src-8edfd124b2fb597b54de", "source_type": "PUBMED_RECORD", "tier": 1, "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/32445440/", "external_identifier": "32445440", "publisher": "The New England journal of medicine", "published_at": "2020 Nov 5", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "e1948448f118d49ff869d3ee950273b4d685748a6cb75cbfb94bb285923b9193", "snapshot_locator": null, "status": "CURRENTLY_RETRIEVED" }, "relationship": "DIRECT_TRIAL_PUBLICATION", "relationship_basis": "PubMed indexed record returned for exact NCT04280705 identifier query", "confidence": 1 } ], "changes": [], "contradictions": [], "unknowns": [ "collaborators" ], "evidence_manifest": { "manifest_version": "ud-trial-provenance/0.1", "pack_id": "tpp-23c7359f72fc95c70cf74fcb", "trial_id": "NCT04280705", "generated_at": "2026-09-21T15:03:31.075Z", "software_version": "0.1.0", "policy_version": "clinical-trial-provenance/0.1", "ordered_sources": [ { "source_id": "src-0714e354de52ea589705", "canonical_url": "https://clinicaltrials.gov/study/NCT04280705", "retrieved_at": "2026-09-21T15:03:27.536Z", "content_hash": "5b010cf5754d3deb521279f616257b7cba726dd290ec972f65ffd6bde8f3eb68", "tier": 1 }, { "source_id": "src-1088878b86de4a9de905", "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/36442063/", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "1df93cf2e44f596e0bb9fb24f09141ae88de02059b141a0cae091e9f8fe555b9", "tier": 1 }, { "source_id": "src-280ba46f5c13688192fc", "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/38618926/", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "ee7e5aa9bb7e37fe7d7ed0d9b7b1bca4388d606ab855cf90a916453acb4fd3f2", "tier": 1 }, { "source_id": "src-305c36d00080bbb08a75", "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/34350582/", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "8d6a4c53124a52cdb153b2522e1958c4d4e280384bc73ddbf972f1f418ea8b33", "tier": 1 }, { "source_id": "src-4daa19a90a25dd5e6723", "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/34473343/", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "5c89b68bdfd8c14fd1269375128cf43e70345ae275e48efdefc198b2b6e43ac6", "tier": 1 }, { "source_id": "src-6f87ad713e55332e03b9", "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/36695483/", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "c8b1f8c501ee03038c43e67baa261848216b51415b8689b0477d6c652b15c8c6", "tier": 1 }, { "source_id": "src-8edfd124b2fb597b54de", "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/32445440/", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "e1948448f118d49ff869d3ee950273b4d685748a6cb75cbfb94bb285923b9193", "tier": 1 }, { "source_id": "src-a372d48de6ecf155eb2a", "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/37466213/", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "bc4e4c5d1d8333010c92d472d492c82d4ac6e52c7bb0af5ca3ee2d42b00ea0ed", "tier": 1 }, { "source_id": "src-a87c29d74e6d92ae5bd1", "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/32969710/", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "1dd84b64a9a198211c99a52910c65b84843abbf9e3001233adb9dced091c21ab", "tier": 1 }, { "source_id": "src-e20c7e961d6eb8b0972c", "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/33240091/", "retrieved_at": "2026-09-21T15:03:31.075Z", "content_hash": "16e5379d39a6d44b6c55415c7e55f532ff24a5e4e86693134793b7bef2756ca6", "tier": 1 }, { "source_id": "src-e33b53de92a28214a7ed", "canonical_url": "https://pubmed.ncbi.nlm.nih.gov/38657001/", "retrieved_at": "2026-09-21T15:03:31.074Z", "content_hash": "0e4c46e6096860920954c473770ab217390bb2e5b0af1912a89fa666047aac8e", "tier": 1 } ], "claims_digest": "29783d65879fca21e064fec112c543e875db3ebd589022d953dd4a2139205357", "field_observations_digest": "33839bf6bb289dc861b6a7b12b4a344c5aa451c4365a103f26edd5f12dbd6c89", "change_events_digest": "4f53cda18c2baa0c0354bb5f9a3ecbe5ed12ab4d8e11ba873c2f11161202b945", "contradictions_digest": "4f53cda18c2baa0c0354bb5f9a3ecbe5ed12ab4d8e11ba873c2f11161202b945", "trust_state": { "integrity": "INTEGRITY VERIFIED", "signer_identity": "NOT CHECKED", "timestamp": "LOCAL SIGNED TIME ONLY", "current_status": "NOT CHECKED", "transparency": "NOT PRESENT" }, "manifest_digest": "79953862de481af42627d30238a1b84b2f8a936861c8f0c4829601ca0c41233a" } }